These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28198434)

  • 61. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
    Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
    J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.
    Liu B; Liu Z; Chen S; Ki M; Erickson C; Reis-Filho JS; Durham BH; Chang Q; de Stanchina E; Sun Y; Rabadan R; Abdel-Wahab O; Chandarlapaty S
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33031100
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin.
    Vanzyl EJ; Rick KRC; Blackmore AB; MacFarlane EM; McKay BC
    PLoS One; 2018; 13(1):e0191178. PubMed ID: 29338026
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology.
    Kim Guisbert KS; Mossiah I; Guisbert E
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348896
    [TBL] [Abstract][Full Text] [Related]  

  • 65.
    López-Oreja I; Gohr A; Playa-Albinyana H; Giró A; Arenas F; Higashi M; Tripathi R; López-Guerra M; Irimia M; Aymerich M; Valcárcel J; Bonnal S; Colomer D
    Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37562845
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
    Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
    Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fanconi anemia FANCD2 and FANCI proteins regulate the nuclear dynamics of splicing factors.
    Moriel-Carretero M; Ovejero S; Gérus-Durand M; Vryzas D; Constantinou A
    J Cell Biol; 2017 Dec; 216(12):4007-4026. PubMed ID: 29030393
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Degenerate minigene library analysis enables identification of altered branch point utilization by mutant splicing factor 3B1 (SF3B1).
    Gupta AK; Murthy T; Paul KV; Ramirez O; Fisher JB; Rao S; Rosenberg AB; Seelig G; Minella AC; Pillai MM
    Nucleic Acids Res; 2019 Jan; 47(2):970-980. PubMed ID: 30462273
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer.
    Zhang J; Huang J; Xu K; Xing P; Huang Y; Liu Z; Tong L; Manley JL
    Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2216712119. PubMed ID: 36459648
    [No Abstract]   [Full Text] [Related]  

  • 70. Promoting spliceosome assembly for therapeutic intent.
    Lu B; Abdel-Wahab O
    Trends Pharmacol Sci; 2021 Dec; 42(12):981-983. PubMed ID: 34602305
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 72. (G)Patching up mis-splicing in cancer.
    Cieśla M; Bellodi C
    Trends Biochem Sci; 2024 Jul; 49(7):564-566. PubMed ID: 38762373
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
    Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Overlapping roles of spliceosomal components SF3B1 and PHF5A in rice splicing regulation.
    Butt H; Bazin J; Alshareef S; Eid A; Benhamed M; Reddy ASN; Crespi M; Mahfouz MM
    Commun Biol; 2021 May; 4(1):529. PubMed ID: 33953336
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition.
    Potts KS; Cameron RC; Metidji A; Ghazale N; Wallace L; Leal-Cervantes AI; Palumbo R; Barajas JM; Gupta V; Aluri S; Pradhan K; Myers JA; McKinstry M; Bai X; Choudhary GS; Shastri A; Verma A; Obeng EA; Bowman TV
    Cell Rep; 2022 Dec; 41(11):111825. PubMed ID: 36516770
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Understanding and therapeutic targeting of aberrant mRNA splicing mechanisms in oncogenesis].
    Tanaka A; Kobayashi S; Xiao M; Inoue D
    Rinsho Ketsueki; 2020; 61(6):643-650. PubMed ID: 32624538
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Non-canonical functions of spliceosome components in cancer progression.
    Ivanova OM; Anufrieva KS; Kazakova AN; Malyants IK; Shnaider PV; Lukina MM; Shender VO
    Cell Death Dis; 2023 Feb; 14(2):77. PubMed ID: 36732501
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.
    Boddu PC; Gupta AK; Roy R; De La Peña Avalos B; Olazabal-Herrero A; Neuenkirchen N; Zimmer JT; Chandhok NS; King D; Nannya Y; Ogawa S; Lin H; Simon MD; Dray E; Kupfer GM; Verma A; Neugebauer KM; Pillai MM
    Mol Cell; 2024 Apr; 84(8):1475-1495.e18. PubMed ID: 38521065
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Generation of a monoclonal antibody against the mouse Sf3b1 (SAP155) gene product for U2 snRNP component of spliceosome.
    Horie A; Isono K; Koseki H
    Hybrid Hybridomics; 2003 Apr; 22(2):117-9. PubMed ID: 12831537
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeting splicing abnormalities in cancer.
    Agrawal AA; Yu L; Smith PG; Buonamici S
    Curr Opin Genet Dev; 2018 Feb; 48():67-74. PubMed ID: 29136527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.